Sign In
Buy MTLS
Materialise NV Earnings Calls
| Release date | Oct 28, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0400 |
| EPS Surprise | 300.00% |
| Revenue estimate | 70.73M |
| Revenue actual | 77.751M |
| Revenue Surprise | 9.93% |
| Release date | Jul 24, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0040 |
| EPS Surprise | -60.30% |
| Revenue estimate | 67.28M |
| Revenue actual | 76.335M |
| Revenue Surprise | 13.46% |
| Release date | Apr 24, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | -$0.0100 |
| EPS Surprise | -150.00% |
| Revenue estimate | 67.205M |
| Revenue actual | 72.768M |
| Revenue Surprise | 8.28% |
| Release date | Feb 20, 2025 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0500 |
| Revenue estimate | 63.1M |
| Revenue actual | 68.011M |
| Revenue Surprise | 7.78% |
Last 4 Quarters for Materialise NV
Below you can see how MTLS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 20, 2025 |
| Price on release | $5.96 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0500 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $9.41 |
| Feb 14, 2025 | $9.62 |
| Feb 18, 2025 | $9.28 |
| Feb 19, 2025 | $9.22 |
| Feb 20, 2025 | $5.96 |
| Feb 21, 2025 | $5.90 |
| Feb 24, 2025 | $6.10 |
| Feb 25, 2025 | $5.38 |
| Feb 26, 2025 | $5.40 |
| 4 days before | -36.66% |
| 4 days after | -9.40% |
| On release day | -1.01% |
| Change in period | -42.61% |
| Release date | Apr 24, 2025 |
| Price on release | $5.29 |
| EPS estimate | $0.0200 |
| EPS actual | -$0.0100 |
| EPS surprise | -150.00% |
| Date | Price |
|---|---|
| Apr 17, 2025 | $4.72 |
| Apr 21, 2025 | $4.51 |
| Apr 22, 2025 | $4.63 |
| Apr 23, 2025 | $4.63 |
| Apr 24, 2025 | $5.29 |
| Apr 25, 2025 | $5.16 |
| Apr 28, 2025 | $5.16 |
| Apr 29, 2025 | $5.21 |
| Apr 30, 2025 | $5.14 |
| 4 days before | 12.08% |
| 4 days after | -2.84% |
| On release day | -2.46% |
| Change in period | 8.90% |
| Release date | Jul 24, 2025 |
| Price on release | $5.33 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0040 |
| EPS surprise | -60.30% |
| Date | Price |
|---|---|
| Jul 18, 2025 | $5.84 |
| Jul 21, 2025 | $6.01 |
| Jul 22, 2025 | $6.06 |
| Jul 23, 2025 | $6.18 |
| Jul 24, 2025 | $5.33 |
| Jul 25, 2025 | $5.33 |
| Jul 28, 2025 | $5.31 |
| Jul 29, 2025 | $5.31 |
| Jul 30, 2025 | $5.25 |
| 4 days before | -8.82% |
| 4 days after | -1.41% |
| On release day | 0% |
| Change in period | -10.10% |
| Release date | Oct 28, 2025 |
| Price on release | $5.70 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0400 |
| EPS surprise | 300.00% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $5.93 |
| Oct 23, 2025 | $6.08 |
| Oct 24, 2025 | $6.04 |
| Oct 27, 2025 | $5.94 |
| Oct 28, 2025 | $5.70 |
| Oct 29, 2025 | $5.48 |
| Oct 30, 2025 | $5.66 |
| Oct 31, 2025 | $6.40 |
| Nov 03, 2025 | $6.60 |
| 4 days before | -3.88% |
| 4 days after | 15.79% |
| On release day | -3.86% |
| Change in period | 11.30% |
Materialise NV Earnings Call Transcript Summary of Q3 2025
Materialise reported Q3 2025 revenue of EUR 66.3m, down 3.5% year-over-year but up 2% versus Q2. Key strengths: Medical achieved an all-time quarterly record (EUR 33.3m), +10% y/y driven by both software and medical device sales, with double-digit growth and continued R&D investment (over EUR 11m in Q3). Strategic progress in cardiac planning following the FEops acquisition (new TAVR planning features and clinical evidence showing large time savings) and new AI-enabled releases for CMF/trauma. Software revenue declined 7% (EUR 10.3m) but the cloud subscription transition continues: recurring revenue rose to ~83% of software revenue. Manufacturing remains the main drag, down 17% y/y (EUR 22.7m), impacted by macro headwinds (notably automotive); ACTech investments target large/heavy parts and defense/aerospace opportunities. Profitability: gross margin strong at 56.8%; adjusted EBIT EUR 2.9m (4.4% margin); adjusted EBITDA EUR 8.4m (12.7% margin). Cash/Balance sheet: cash reserves EUR 132m, gross debt EUR 64m (incl. EUR 50m drawing in Q3), net cash EUR 67.7m; strong free cash flow YTD and positive FCF (~EUR 11m). Guidance maintained for full-year 2025: revenue EUR 265–280m and adjusted EBIT EUR 6–10m. Management emphasizes disciplined cost control, continued Medical investment, cloud transition for Software, and awaiting manufacturing market recovery (esp. automotive and European industrial demand).
